Inhibrx, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 78.71 million compared to USD 48.92 million a year ago. Basic loss per share from continuing operations was USD 1.44 compared to USD 1.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.17 USD | -4.72% | -49.66% | -54.82% |
06-04 | Inhibrx Biosciences Insider Bought Shares Worth $4,927,580, According to a Recent SEC Filing | MT |
05-31 | Inhibrx, Inc.(NasdaqGM:INBX) dropped from S&P Biotechnology Select Industry Index | CI |
1st Jan change | Capi. | |
---|---|---|
-54.82% | 1.79B | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- INBX Stock
- News Inhibrx, Inc.
- Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024